Prostate cancer, the most common type of cancer, is the second leading cause of cancer death in American men next to lung cancer. September is observed as the national prostate cancer awareness month. This is the perfect time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options, and resources that offer updated prostate cancer information throughout the year. A light blue ribbon is used to designate prostate cancer awareness.
This cancer type develops in the tissues of the prostate, below the bladder and in front of the rectum. Family history, race and ethnicity, hormones, diet and inflammation of the prostate are certain risk factors that increase the chance of developing prostate cancer.
According to the statistics from the American Cancer Society, in 2014 about 233,000 new cases of prostate cancer will be diagnosed and about 29,480 men will die of this disease. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.
Regular screenings can help in early detection of prostate cancer. The American Cancer Society advises that men with an average risk for prostate cancer should discuss screening with their doctors around age 50, while men with high risk factors such as African American men with a family history of the disease, should consider testing as early as age 40.
Staying informed with the latest news on prevention and screening is an important step in reducing your risk of developing prostate cancer. Cancer screening tests – including the prostate-specific antigen (PSA) test can help identify prostate cancer early, when treatment is most effective.
Beckman Coulter, Inc. is the leading manufacturer of PSA reagents and calibrators for PSA assays. Access Hybritech free PSA Reagent that is refrigerated at 2° to 10°C for a minimum of two hours before use on the instrument, and Access Hybritech free PSA Calibrators are the products that assist in the tests.